BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin I, Baldomero H, Bocelli-Tyndall C, Emmert MY, Hoerstrup SP, Ireland H, Passweg J, Tyndall A. The survey on cellular and engineered tissue therapies in Europe in 2011. Tissue Eng Part A 2014;20:842-53. [PMID: 24090467 DOI: 10.1089/ten.TEA.2013.0372] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Wang S, Zhou Y, Andreyev O, Hoyt RF Jr, Singh A, Hunt T, Horvath KA. Overexpression of FABP3 inhibits human bone marrow derived mesenchymal stem cell proliferation but enhances their survival in hypoxia. Exp Cell Res 2014;323:56-65. [PMID: 24583397 DOI: 10.1016/j.yexcr.2014.02.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
2 Gay MHP, Baldomero H, Farge-Bancel D, Robey PG, Rodeo S, Passweg J, Müller-Gerbl M, Martin I. The Survey on Cellular and Tissue-Engineered Therapies in Europe in 2016 and 2017. Tissue Eng Part A 2021;27:336-50. [PMID: 32680446 DOI: 10.1089/ten.TEA.2020.0092] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Passweg JR, Baldomero H, Peters C, Gaspar HB, Cesaro S, Dreger P, Duarte RF, Falkenburg JH, Farge-Bancel D, Gennery A, Halter J, Kröger N, Lanza F, Marsh J, Mohty M, Sureda A, Velardi A, Madrigal A; European Society for Blood and Marrow Transplantation EBMT. Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplant 2014;49:744-50. [PMID: 24637898 DOI: 10.1038/bmt.2014.55] [Cited by in Crossref: 110] [Cited by in F6Publishing: 96] [Article Influence: 13.8] [Reference Citation Analysis]
4 Baugé C, Boumédiene K. Use of Adult Stem Cells for Cartilage Tissue Engineering: Current Status and Future Developments. Stem Cells Int 2015;2015:438026. [PMID: 26246809 DOI: 10.1155/2015/438026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
5 Martin I, Ireland H, Baldomero H, Dominici M, Saris DB, Passweg J. The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013. Tissue Engineering Part A 2016;22:5-16. [DOI: 10.1089/ten.tea.2015.0416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
6 Martin I, Ireland H, Baldomero H, Passweg J. The survey on cellular and engineered tissue therapies in Europe in 2012. Tissue Eng Part A 2015;21:1-13. [PMID: 25425342 DOI: 10.1089/ten.TEA.2014.0515] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
7 Koliakos G. Stem Cells and Aging. Rejuvenation Research 2017;20:4-8. [DOI: 10.1089/rej.2016.1809] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Todorov A, Kreutz M, Haumer A, Scotti C, Barbero A, Bourgine PE, Scherberich A, Jaquiery C, Martin I. Fat-Derived Stromal Vascular Fraction Cells Enhance the Bone-Forming Capacity of Devitalized Engineered Hypertrophic Cartilage Matrix. Stem Cells Transl Med 2016;5:1684-94. [PMID: 27460849 DOI: 10.5966/sctm.2016-0006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Davies BM, Rikabi S, French A, Pinedo-Villanueva R, Morrey ME, Wartolowska K, Judge A, MacLaren RE, Mathur A, Williams DJ, Wall I, Birchall M, Reeve B, Atala A, Barker RW, Cui Z, Furniss D, Bure K, Snyder EY, Karp JM, Price A, Carr A, Brindley DA. Quantitative assessment of barriers to the clinical development and adoption of cellular therapies: A pilot study. J Tissue Eng 2014;5:2041731414551764. [PMID: 25383173 DOI: 10.1177/2041731414551764] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]